stockrow
Friday 6 November 2026
Export BLCO’s income statement to Excel — free account
Bausch + Lomb Corporation
BLCO Healthcare Medical Instruments & Supplies
Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024.
- Revenue
- +7.34%
- EPS
- +222.4%
- Free cash flow
- +182.5%
- Total debt
- +2.93%
Quarter to September 2026, against a year earlier
19.94
0.66
−3.20%
Follow BLCO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.18 | 1.08 | 1.11 | 1.12 | |
P/FCF ratio |
0.00 | 0.00 | 52.80 | 26.78 | |
P/Operating CF |
44.43 | 176.49 | 38.65 | 26.09 | |
P/B ratio |
0.93 | 0.88 | 0.92 | 0.93 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.10 | 2.00 | 2.00 | 1.97 | |
EV/EBITDA |
19.43 | 15.79 | 14.22 | 13.31 | |
EV/Operating CF |
37.91 | 30.70 | 23.25 | 19.24 | |
EV/FCF |
(117.89) | (434.94) | 95.09 | 46.96 | |
Quick Ratio |
0.84 | 0.76 | 0.81 | 0.85 | |
Current Ratio |
1.55 | 1.53 | 1.55 | 1.56 | |
Net Debt/EBITDA |
21.79 | 34.97 | 25.06 | 17.62 | |
Debt/Assets |
36.24% | 36.79% | 36.91% | 36.50% | |
Debt/Equity |
0.78 | 0.79 | 0.79 | 0.78 | |
Asset Turnover |
0.37 | 0.38 | 0.38 | 0.39 | |
Operating CF/Net income |
(2.34) | (0.45) | (10.93) | 7.28 | |
Capex/Depreciation |
(0.74) | (0.96) | (0.67) | (0.52) | |
Interest Coverage |
1.14 | 0.34 | 0.89 | 1.63 | |
Research and Development Expense of Revenue |
6.69% | 8.12% | 8.18% | 6.62% | |
Selling, General and Administrative Expense of Revenue |
40.14% | 43.73% | 42.18% | 40.44% | |
Intangible Assets out of Total Assets |
0.57 | 0.58 | 0.57 | 0.56 | |
Share Based Compensation of Revenue |
4.56% | 2.73% | 2.73% | 2.69% | |
Graham Net Nets |
(0.75) | (0.81) | (0.76) | (0.72) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(5.97%) | (3.90%) | (2.90%) | (1.78%) | |
Free Cash Flow Yield |
(1.51%) | (0.42%) | 1.89% | 3.73% | |
Revenue per Share |
3.97 | 3.50 | 3.90 | 3.85 | |
Operating CF per Share |
0.38 | 0.09 | 0.43 | 0.65 | |
Capex per Share |
(0.21) | (0.28) | (0.20) | (0.15) | |
Free Cash Flow per Share |
0.17 | (0.19) | 0.23 | 0.50 | |
Cash per Share |
1.12 | 0.79 | 1.06 | 1.44 | |
Shareholders Equity per Share |
18.43 | 18.16 | 18.05 | 18.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
18.43 | 18.16 | 18.05 | 18.20 | |
Free Cash Flow |
60.00 | (68.00) | 82.00 | 178.00 | |
Working Capital |
1,057.00 | 956.00 | 1,032.00 | 1,095.00 | |
Capital Expenditures |
(76.00) | (100.00) | (71.00) | (55.00) | |
Net Current Asset Value |
(4,526.00) | (4,552.00) | (4,493.00) | (4,394.00) | |
EV/EBIT |
94.94 | 45.58 | 32.97 | 27.83 | |
Capex to Sales |
0.05 | 0.08 | 0.05 | 0.04 | |
Price to Operating Income |
53.48 | 24.66 | 18.31 | 15.87 | |
| Other line items | |||||
Average Receivables |
1,123.50 | 1,056.50 | 1,122.00 | 1,118.00 | |
Average Payables |
388.50 | 417.00 | 437.50 | 381.00 | |
Average Inventory |
1,006.00 | 1,004.00 | 1,025.00 | 1,006.00 | |
Average Assets |
13,745.50 | 13,604.00 | 13,845.50 | 13,895.50 | |
Average Common Equity |
6,531.50 | 6,442.50 | 6,476.00 | 6,505.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026